Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
- Resource Type
- Article
- Authors
- Smith, Gale E.; Flyer, David C.; Raghunandan, Ramadevi; Liu, Ye; Wei, Ziping; Wu, Yingyun; Kpamegan, Eloi; Courbron, Denise; Fries, Louis F.; Glenn, Gregory M.
- Source
- Vaccine. Sep2013, Vol. 31 Issue 40, p4305-4313. 9p.
- Subject
- *H7N9 Influenza
*DRUG development
*ANIMAL vaccination
*LABORATORY mice
*INFLUENZA viruses
*HEMAGGLUTININ
*GLYCOPROTEINS
- Language
- ISSN
- 0264-410X
Highlights: [•] Recombinant A/Anhui/1/2013 (H7N9) HA, NA and avian M1 form virus like particles. [•] A(H7N9) VLP form enveloped particles containing HA and NA glycoproteins. [•] A(H7N9) VLP vaccine induced hemagglutinin inhibition (HAI) titers ≥1:64. [•] A(H7N9) VLP vaccine 100% protective against wild type A/Anhui/1/2013 (H7N9) influenza challenge. [•] A(H7N9) VLP vaccine in vivo data support clinical development in man. [ABSTRACT FROM AUTHOR]